Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label single-arm phase IV study of huperzine-related tetrahydroaminoacridine succinate tablets in mild to moderate Alzheimer's disease
CTR20263269Phase 4Active
- Sponsor
- Changchun Huayang High-tech Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tacrine in Alzheimer's disease (AD), sponsored by Changchun Huayang High-tech Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
tacrine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20263269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263269.